登录新浪财经APP 搜索【信披】查看更多考评等级 专题：2024年度A股独立董事数据报告 独立董事制度作为资本市场基础制度的重要内容，是上市公司治理结构的重要一环，其核心职责即通过监督制衡，促进上市公司规范运作、提升信息披露的透明度与真实性，保护中小投资者利益 郭永清，2024年期间担任上海电力独立董事、建元信托独立董事、新华保险独立董事，分别于2021年06月17日、2022年09月26日、2022年12月任职。2024年，郭永清先生从三家公司获得的 2024年任职期间，上海电力共计召开13次董事会、3次股东大会，郭永清先生亲自出席所有应参加的董事会，并出席2次股东大会。同时，对公司董事会审议的各项议案均投以同意票，没有提出 2024年任职期间，建元信托共计召开9次董事会、2次股东大会，郭永清先生参加上述全部会议。同时，对公司董事会审议的各项议案均投以同意票，没有提出异议的事项，也没有反对或弃权的 2024年任职期间，新华保险共计召开14次董事会、3次股东大会，郭永清先生参加上述全部会议。同时，对公司董事会审议的各项议案均投以同意票，没有提出异议的事项，也没有反对或弃权的 据履历显示，郭永清先生具有注册会计 ...

建元信托股份有限公司公告 因不服上述判决，东证资管提起上诉，请求上海市高级人民法院撤销上海金融 法院作出的（2020）沪 74 民初 2489 号《民事判决书》，改判支持上诉人一审全部 诉讼请求。公司于 2025 年 8 月 19 日收到上海市高级人民法院通知及《传票》，上 海市高级人民法院已受理上诉案件，案号为（2025）沪民终 419 号。 二、相关诉讼事项对公司本期利润或者期后利润等的影响 二审案件尚未开庭，目前暂无法判断相关诉讼对公司本期利润或者期后利润的 影响。公司将依据法律规定程序，积极行使诉讼权利。 公司指定的信息披露媒体为《中国证券报》《证券日报》《上海证券报》和上 证券代码：600816 证券简称：建元信托 公告编号：临 2025-026 建元信托股份有限公司 诉讼进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏, 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、前期诉讼进展情况 公司前期于《诉讼公告暨前期诉讼进展公告》（编号：临 2020-060）、《诉讼 进展公告》（编号：临 2025-014）中披露了涉及上海东方证券资产管理 ...

Group 1 - The core point of the article highlights the financing activities of Jianyuan Trust, which recorded a financing purchase amount of 0.24 billion yuan on August 19, ranking 962nd in the two markets [1] - Over the last three trading days from August 15 to August 19, Jianyuan Trust received financing purchases of 0.27 billion yuan, 0.29 billion yuan, and 0.24 billion yuan respectively [1] - On the same day, the company experienced a securities lending activity with a sell-off of 20.93 thousand shares, resulting in a net sell-off of 15.37 thousand shares [1]

Core Viewpoint - Qianhong Pharmaceutical has reached a settlement with Jianyuan Trust to recover half of its investment in the "Chuangying 51" trust plan after a five-year dispute, highlighting the ongoing challenges faced by companies in managing trust investments and the impact of external economic conditions on asset performance [2][3][4]. Group 1: Settlement Details - On August 14, Qianhong Pharmaceutical announced it had reached a settlement with Jianyuan Trust regarding the "Chuangying 51" trust plan, resulting in a one-time payment of 56.9943 million yuan, which will be recognized as approximately 48.45 million yuan in profit for the 2025 fiscal year [2][5]. - The total investment in the two trust products purchased in 2018 amounted to 340 million yuan, with both products experiencing overdue payments [3][4]. - The settlement allows Qianhong to retain part of the trust beneficiary rights, indicating a strategy to balance risk while recovering some capital [6]. Group 2: Background of Trust Products - The "Chuangying 51" trust plan was set to mature on December 29, 2019, while the "Ruiying 64" plan was due on August 15, 2019, but both faced overdue payments due to the underlying assets' lack of liquidity and the borrower's financial difficulties [3][4]. - The total amount involved in the lawsuits against Jianyuan Trust was approximately 376.1866 million yuan, with overdue principal totaling 340 million yuan [4]. Group 3: Industry Context - The trend of companies facing challenges with trust investments is not isolated, as evidenced by other firms like Hengyin Technology and Chengdu Road and Bridge, which have also reported significant overdue amounts from trust products [7]. - The current economic environment has led to a preference for lower-risk fixed-income products among listed companies, with 36 companies reportedly investing a total of approximately 8.9 billion yuan in trust products since early 2025, reflecting a shift in investment strategy [7].

Core Viewpoint - Qianhong Pharmaceutical reached a settlement with Jianyuan Trust regarding a payment dispute from a trust plan purchased in 2018, resulting in a one-time payment of 56.9943 million yuan, which will contribute approximately 48.45 million yuan to the company's 2025 profit [1][4]. Group 1: Qianhong Pharmaceutical - Qianhong Pharmaceutical invested 170 million yuan in the "Anxin Chuangyin 51 Hao" trust plan, which was originally due on December 29, 2019 [4]. - After a prolonged legal battle lasting five years, the company agreed to withdraw its lawsuit in exchange for half of the remaining principal and earnings, amounting to 56.9943 million yuan [4]. - The expected profit increase of approximately 48.45 million yuan will be recorded in the 2025 profit statement [4]. Group 2: Jianyuan Trust - Jianyuan Trust reported a total revenue of 150 million yuan for the first half of 2025, marking an 84.89% year-on-year increase, and a net profit of 40 million yuan, up 13.36% [4][5]. - The company added 117 new trust projects in the first half of 2025, corresponding to a new trust scale of 1,080.01 billion yuan, reflecting a 785% year-on-year growth [5]. - As of June 30, 2025, Jianyuan Trust's managed trust assets reached 3,378.91 billion yuan, a 33.44% increase from the beginning of the year [5]. Group 3: Financial Performance and Business Development - In 2024, Jianyuan Trust achieved total revenue of 310 million yuan, with a net profit of 53 million yuan, representing a 25.15% year-on-year growth [7]. - The company’s solid business became a significant pillar, with interest income from proprietary business increasing by 12% to 32.5149 million yuan [7]. - Jianyuan Trust's trust asset management scale reached 2,532 billion yuan by the end of 2024, with a substantial growth of 78% from the beginning of the year [7].

Core Viewpoint - The announcement details the litigation progress of Jianyuan Trust Co., Ltd., including settlements and arbitration outcomes, which may impact the company's financials. Group 1: Litigation Status - One case has been settled and withdrawn, one arbitration ruling has been revoked, and one case has been withdrawn [2] - The company is a defendant in the settled and withdrawn cases, while it is the applicant in the revoked arbitration case [2] Group 2: Financial Implications - The settled case involved a litigation amount of 177.87 million yuan, the revoked arbitration case involved a principal amount of 10 million yuan, and the withdrawn case involved 365,600 yuan [2] - The company will recognize liabilities based on the settlement results for the settled case, and will reverse previously recognized liabilities for the revoked arbitration case [2][7] Group 3: Specific Case Details - In the case involving Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., a settlement agreement was signed on August 13, 2025, with the company paying 56.99 million yuan [3][4] - The company received a civil ruling allowing the withdrawal of the case, with the litigation costs borne by Changzhou Qianhong [4] Group 4: Other Litigation Developments - In the case involving Haoke Technology Co., Ltd., the company was ordered to return a trust principal of 10 million yuan, but the arbitration ruling was later revoked by the Shanghai Financial Court [5][6] - A separate case involving a natural person had its claim amount adjusted from 1.6 million yuan to 365,600 yuan [7]

建元信托股份有限公司公告 建元信托股份有限公司 诉讼进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏, 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、前期诉讼进展情况 （一）涉及常州千红生化制药股份有限公司的案件 公司前期于《诉讼公告暨前期诉讼进展公告》（编号：临 2020-006）中披露了 涉及常州千红生化制药股份有限公司（以下简称"常州千红制药公司"）的 1 宗案 件（案号为"（2020）沪 74 民初 3 号"，以下简称"本案"），该案件原告为常州 千红制药公司，被告为本公司，涉诉金额 17,786.94 万元。 2025 年 8 月 13 日，经双方友好协商，公司与常州千红制药公司签署《和解协 议》。根据《和解协议》（以下简称"本协议"），本协议签署当日，本公司向常 州千红制药公司支付和解款 5,699.43 万元；常州千红制药公司向上海金融法院提交 案件所处的诉讼阶段：1 宗案件已和解并撤诉，1 宗案件已撤销仲裁裁决，1 宗案件已撤诉。 建元信托股份有限公司（以下简称"公司"、"本公司"）所处的当事人地 位：已和解并撤诉案件、已撤诉案件 ...

Group 1: Guizhou Moutai - Guizhou Moutai achieved a net profit of 45.403 billion yuan in the first half of 2025, an increase of 8.89% year-on-year [1] - The company's operating income for the same period was 89.389 billion yuan, reflecting a growth of 9.1% year-on-year [1] - Basic earnings per share were reported at 36.18 yuan per share [1] Group 2: Weixing New Materials - Weixing New Materials reported a net profit of 271 million yuan in the first half of 2025, a decrease of 20.25% year-on-year [1] - The company's operating income was 2.078 billion yuan, down 11.33% year-on-year [1] - The company plans to distribute a cash dividend of 1 yuan per 10 shares [1] Group 3: Jianyuan Trust - Jianyuan Trust's net profit for the first half of 2025 was 40.2897 million yuan, an increase of 13.36% year-on-year [1] - The company achieved an operating income of 15 million yuan, a significant growth of 84.89% year-on-year [1] - Basic earnings per share were reported at 0.0041 yuan per share [1][2] Group 4: Weili - Weili won a bid for a leachate treatment project, expected to generate an annual revenue of approximately 61 million yuan [1] - The project has a total expected revenue of about 610 million yuan over a 10-year operational period [1] - The project includes a 0.5-year construction period followed by a 10-year operational period [1] Group 5: Tianjun Wind Power - Tianjun Wind Power provided a guarantee for a credit line of 150 million yuan for its wholly-owned subsidiary [1] - The guarantee covers the principal amount, interest, penalties, and other related costs [1] - The guarantee period is three years from the maturity of the main contract [1] Group 6: Jiangshan Oupai - Jiangshan Oupai's wholly-owned subsidiary completed the registration for a change in business type [1] - The subsidiary is now classified as a limited liability company [1] Group 7: Ningbo Port - Ningbo Port announced the resignation of independent director Yan Guoqing due to personal reasons [1] Group 8: Yangfan New Materials - Yangfan New Materials reported a net profit of 23.1372 million yuan in the first half of 2025, marking a turnaround from losses [1] - The company's total operating revenue was 473 million yuan, an increase of 47.93% year-on-year [1] Group 9: Zhongguancun - Zhongguancun's subsidiary received a drug registration certificate for a new injection [1] - The company also announced that another product passed the consistency evaluation for generic drugs [1] Group 10: Hengtong Oriental - Hengtong Oriental is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] Group 11: Quzhou Development - Quzhou Development plans to acquire 95.46% of Xian Dao Electronics and will resume trading on August 13, 2025 [1] Group 12: Jiangsu Sop - Jiangsu Sop reported a net profit of 102 million yuan in the first half of 2025, a decrease of 13.01% year-on-year [1] - The company's operating income was 3.158 billion yuan, down 1.08% year-on-year [1] Group 13: Fudan Fuhua - Fudan Fuhua's subsidiary plans to invest 48.87 million yuan in a capital increase for another company [1] Group 14: Shaanxi Huada - Shaanxi Huada is planning to acquire 100% of Huajing Microelectronics and has suspended trading [1]

Group 1 - The core viewpoint of the article highlights the financial performance of Jianyuan Trust for the first half of 2025, showcasing significant growth in revenue while facing a decline in total profit [1] Group 2 - The company achieved total operating revenue of 150 million yuan, representing a year-on-year increase of 84.89% [1] - The total profit amounted to 36 million yuan, reflecting a year-on-year decrease of 12.76% [1] - The net profit attributable to shareholders reached 40 million yuan, with a year-on-year growth of 13.36% [1]

Core Viewpoint - The report highlights the financial performance and strategic direction of J-Yuan Trust Co., Ltd. for the first half of 2025, showcasing significant growth in revenue and net profit while emphasizing the company's commitment to transforming its business model in line with regulatory changes in the trust industry [1][2]. Financial Performance - Total operating revenue for the first half of 2025 reached CNY 149.73 million, an increase of 84.89% compared to CNY 80.99 million in the same period last year [2][7]. - The net profit attributable to shareholders was CNY 40.29 million, reflecting a year-on-year growth of 13.36% from CNY 35.54 million [2][7]. - The company's total assets increased by 5.20% to CNY 25.12 billion from CNY 23.88 billion at the end of the previous year [2][7]. - The net asset attributable to shareholders rose by 3.00% to CNY 14.11 billion compared to CNY 13.70 billion at the end of the previous year [2][7]. Industry Overview - The trust industry in China is undergoing significant transformation, with a focus on returning to core trust services and enhancing asset management capabilities [3][4]. - As of the end of 2024, the total trust assets in the industry reached CNY 29.56 trillion, marking a 9.48% increase from mid-2024 and a 23.58% increase from the end of 2023 [3][4]. - The industry is shifting from traditional non-standard financing to more diversified and professional asset service trusts, with asset service trust scale approaching CNY 11 trillion, accounting for 40% of the total [3][4]. Business Strategy - The company aims to enhance its service offerings by focusing on risk management, asset securitization, and innovative financial products to better serve the real economy [6][8]. - In the first half of 2025, the company established 117 new trust projects, corresponding to a new trust scale of CNY 1.08 trillion, a remarkable increase of 785% year-on-year [6][8]. - The company is actively exploring new business models and enhancing its asset management capabilities, particularly in the areas of infrastructure and equity projects [8][10]. Risk Management - The company emphasizes a robust risk management framework, integrating risk identification, assessment, monitoring, and response into its strategic planning and operational processes [9][10]. - Continuous improvement of compliance and internal control mechanisms is a priority to ensure sustainable development and mitigate potential risks [9][10]. Talent and Technology Development - The company is committed to building a professional talent team, having recruited 20 new professionals in key strategic areas during the reporting period [9][10]. - A focus on digital transformation is evident, with initiatives aimed at enhancing operational efficiency and customer service through advanced technology and data management [10][11].